Edwards Lifesciences (EW) PT Raised to $139 at UBS Amid Strong Q2
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Edwards Lifesciences Reports Second Quarter Results
July 26, 2016 4:15 PM EDTIRVINE, Calif., July 26, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2016.
Second Quarter Highlights:
Sales grew 23.1% to $759.3 million; underlying1 sales were up 21% Global Transcatheter Heart Valve Therapy (THVT) sales grew 48.7%; underlying grew 45% U.S. THVT sales were up 71.5%; underlying grew 66% GAAP EPS was $0.58, an increase of 13.7%; adjusted2 EPS grew 33% to $0.76 2016... More